Inventor
KIENY MARIE-PAULE
FR18 patents
⚠️ This page may combine multiple inventors who share the name “KIENY MARIE-PAULE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TRANSGENE SA
17 patentsUS5795577AAug 18, 1998
Viral vector coding for a glycoprotein of the virus responsible for A.I.D.S.
TRANSGENE SA46 citations95
US6884786B1Apr 26, 2005
Antitumoral composition based on immunogenic polypeptide with modified cell location
TRANSGENE SA46 citations94
US6007806ADec 28, 1999
Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
TRANSGENE SA77 citations94
US5861381AJan 19, 1999
Pharmaceutical composition for the treatment of a malignant tumor
TRANSGENE SA55 citations94
US7488482B2Feb 10, 2009
Pharmaceutical compositions for treating papillomavirus tumors and infection
TRANSGENE SA24 citations91
US7118754B1Oct 10, 2006
Pharmaceutical composition for treating papillomavirus tumors and infection
TRANSGENE SA22 citations91
US5744133AApr 28, 1998
Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
TRANSGENE SA48 citations90
US5169763ADec 8, 1992
Viral vector coding glycoprotein of HIV-1
TRANSGENE SA23 citations89
US7670607B2Mar 2, 2010
Pharmaceutical compositions for treating papillomavirus tumors and infection
TRANSGENE SA12 citations82
US6284248B1Sep 4, 2001
Immunogenic compositions comprising soluble, non-cleavable, chimeric HIV-1 gp160-variants
TRANSGENE SA8 citations73
US6024953AFeb 15, 2000
Vaccine against rabies and process for preparation thereof
TRANSGENE SA9 citations72
US5830477ANov 3, 1998
Vaccine against rabies and process for preparation thereof
TRANSGENE SA12 citations72
US5597570AJan 28, 1997
Protein recognized by antibodies raised against native P28 of schistosoma mansoni
TRANSGENE SA8 citations70
US6261799B1Jul 17, 2001
Expression cassettes encoding soluble, non-cleavable, chimeric HIV-1 GP160 variants, their methods of construction, and methods for the production of GP160 variants
TRANSGENE SA2 citations62
US6203795B1Mar 20, 2001
Pharmaceutical composition for the treatment or prevention of a malignant tumor
TRANSGENE SA1 citations61
US5672689ASep 30, 1997
Non-cleavable GP160 glycoproteins of HIV
TRANSGENE SA2 citations59
US6328956B1Dec 11, 2001
Pharmaceutical composition for the treatment or prevention of a malignant tumor
TRANSGENE SA1 citations50